Results 21 to 30 of about 31,601 (273)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study

Frontiers in Oncology, 2023
BackgroundBevacizumab has played an important role in the systemic treatment of patients with advanced non-small-cell lung cancer (NSCLC) without gene mutation.
Zhiting Zhao, Luqing Zhao, Guohao Xia, Jianwei Lu, Jianwei Lu, Bo Shen, Guoren Zhou, Fenglei Wu, Xiao Hu, Jifeng Feng, Shaorong Yu, Shaorong Yu   +11 more
doaj   +1 more source

Pharmacovigilance of Biosimilars [PDF]

, 2013
In lieu of an abstract, here is the article\u27s first paragraph: Biotech industry forms the backbone of the current pharmaceutical products. Seven out of top ten anticipated drugs of the industry in 2014 will be biologics [1].
Chablani, Lipika
core   +2 more sources

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]

, 2018
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group, American Diabetes Association Consensus Panel, Anderson, Bagust, Bagust, Billings, Blak, Boye, Chubb, Control Group, Currie, Donnelly, Duckworth, Evans, Forst, Gaede, Gaede, Giugliano, Grandy, Hammer, Holman, Hunt, Hunt, Hunt, Inzucchi, Ismail-Beigi, Johnston, Lee, Matza, McCabe, Meneghini, Mezquita-Raya, National Institute for Health and Care Excellence (NICE), Nauck, Parekh, Peyrot, Peyrot, Ridderstråle, Russell-Jones, Shi, Stettler, The Forum for Injection Technique (FIT), TREND-UK, UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group, Walz, Wang, Wild   +47 more
core   +1 more source

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends

Frontiers in Pharmacology, 2023
Background: Factors like the number of biosimilar competitors and competitive pricing strategies from originator companies may influence price competition and biosimilar uptake.Objective: The aim of this study was to analyze multiple facets of biosimilar
Elif Car, Arnold G. Vulto, Arnold G. Vulto, Mark Van Houdenhoven, Isabelle Huys, Steven Simoens   +5 more
doaj   +1 more source

Key drivers for market penetration of biosimilars in Europe

Journal of Market Access & Health Policy, 2017
Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available ...
Cécile Rémuzat, Julie Dorey, Olivier Cristeau, Dan Ionescu, Guerric Radière, Mondher Toumi   +5 more
doaj   +1 more source

What do oncologists need to know about biosimilar products?

Chinese Journal of Cancer, 2016
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments.
Linda K. S. Leung, Kevin Mok, Calvin Liu, Stephen L. Chan   +3 more
doaj   +1 more source

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

Терапевтический архив, 2021
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included
O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov   +7 more
doaj   +1 more source

Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines [PDF]

, 2018
Objective: The aim was to critically evaluate well-established regulatory agencies mAb biosimilar guidelines for development and marketing authorization about quality, efficacy and safety and compare to BRICS-TM regulations to identify challenges ...
Anvisa, Castaneda-Hernandez, CBER, CBER, CBER, CBER, CBER, CBER, CBER, CDSCO, CFDA, Christl, Cofepris, Gautam, Lozda, MCC, Minghetti, Olech, Priori, Rushvi, Schiestl   +20 more
core   +5 more sources

Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019. [PDF]

, 2020
The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on biosimilars in pharmacy practice on 10 October 2019.
Chan, Alexandre, Ke, Yu, Tan, Chia Jie
core  

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources